CytomX Retained Earnings Total Equity from 2010 to 2024
| CTMX Stock | USD 1.65 0.02 1.20% |
Retained Earnings Total Equity | First Reported 2015-09-30 | Previous Quarter -726.2 M | Current Value -727.3 M | Quarterly Volatility 186.3 M |
Check CytomX Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CytomX Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2 M, Interest Expense of 2.1 M or Selling General Administrative of 28.8 M, as well as many indicators such as Price To Sales Ratio of 1.07, Dividend Yield of 0.0 or Days Sales Outstanding of 11.76. CytomX financial statements analysis is a perfect complement when working with CytomX Therapeutics Valuation or Volatility modules.
CytomX | Retained Earnings Total Equity |
Latest CytomX Therapeutics' Retained Earnings Total Equity Growth Pattern
Below is the plot of the Retained Earnings Total Equity of CytomX Therapeutics over the last few years. It is the portion of total equity that consists of earnings retained by the company, reinvested in its core business or used to pay debt. CytomX Therapeutics' Retained Earnings Total Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CytomX Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Retained Earnings Total Equity | 10 Years Trend |
|
Retained Earnings Total Equity |
| Timeline |
CytomX Retained Earnings Total Equity Regression Statistics
| Arithmetic Mean | (255,319,621) | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | (96.52) | |
| Mean Deviation | 219,563,462 | |
| Median | (219,465,000) | |
| Standard Deviation | 246,436,401 | |
| Sample Variance | 60730.9T | |
| Range | 623.6M | |
| R-Value | (0.95) | |
| Mean Square Error | 6235.8T | |
| R-Squared | 0.90 | |
| Slope | (52,412,069) | |
| Total Sum of Squares | 850232.6T |
CytomX Retained Earnings Total Equity History
About CytomX Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include CytomX Therapeutics income statement, its balance sheet, and the statement of cash flows. CytomX Therapeutics investors use historical funamental indicators, such as CytomX Therapeutics's Retained Earnings Total Equity, to determine how well the company is positioned to perform in the future. Although CytomX Therapeutics investors may use each financial statement separately, they are all related. The changes in CytomX Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on CytomX Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on CytomX Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in CytomX Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Retained Earnings Total Equity | -561.2 M | -533.1 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| COST | Costco Wholesale Corp | |
| AMZN | Amazon Inc | |
| AVGO | Broadcom |
Additional Tools for CytomX Stock Analysis
When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.